Jump to content


Hang onto your hat: Sclero Forums Upgrade May 14-21, 2017!! The Forums will be offline for up to 4 days, and then will return with an entirely new look and feel.


Photo

Rituximab in diffuse cutaneous systemic sclerosis (SSc): should we be using it today?

B cells and T cells clinical trials

  • Please log in to reply
No replies to this topic

#1 Joelf

Joelf

    Star Ruby Member

  • ISN Root Admin
  • PipPipPipPipPipPipPipPipPipPipPipPipPip
  • 4,902 posts
  • Location:West Sussex

Posted 25 February 2015 - 09:24 AM

Rituximab in diffuse cutaneous systemic sclerosis (SSc): should we be using it today?

 

We summarize the therapeutic use of rituximab in SSc and the basic science evidence suggesting that B cells and autoantibodies are the primary drivers of fibrosis in skin and lung tissue. PubMed, Rheumatology (Oxford), 07/01/2015. (Also see: Causes of Scleroderma: B Cells and T Cells and Scleroderma Clinical Trials)

 

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.


Jo Frowde
ISN Assistant Webmaster
SD World Webmaster
ISN Sclero Forums Manager
ISN News Manager
ISN Hotline Support Specialist
ISN Chat Host
International Scleroderma Network (ISN)